Lead Defendant In Case Targeting Synthetic Drugs Pleads Guilty To Smuggling, Drug Trafficking And Money Laundering Charges
Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

United States Drug Enforcement Administration

  • Get Updates
  • Scam Alert
  • Full Menu
  • English
  • Español

Main Menu

Explore DEA
  • Who We Are
    • About
    • Mission
    • History
    • Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Education and Prevention
    • Drug Information
    • News
    • Campaigns
  • Careers
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
    • FOIA
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
  • Submit A Tip

Breadcrumb

  • Home
  • Lead Defendant In Case Targeting Synthetic Drugs Pleads Guilty To Smuggling, Drug Trafficking And Money Laundering Charges

Lead Defendant In Case Targeting Synthetic Drugs Pleads Guilty To Smuggling, Drug Trafficking And Money Laundering Charges

November 08, 2016
|
Share Article
|
Download Press Release
For Immediate Release
Contact: Rosa Valle-Lopez
Phone Number: (571) 387-5045

SANTA, ANA, Calif. - The lead defendant in an indictment that outlined a wide-reaching conspiracy to smuggle, manufacture and distribute more than $12 million worth of synthetic drugs has pleaded guilty in federal court.  Sean Libbert, 41, of Newport Beach, pleaded guilty yesterday afternoon to a series of charges related to a scheme to distribute drugs commonly called “spice” or “bath salts.”  Some of the drugs in this case nearly killed a victim who ingested them, according to the 16-count indictment filed in June 2014, the first in this district involving drug analogues.
           
Libbert pleaded guilty to four felony offenses: conspiracy to manufacture, possess with intent to distribute, and distribute controlled substance analogues; conspiracy to smuggle controlled substance analogues into the United States using false statements and fraudulent documents; being a felon in possession of firearms and ammunition; and money laundering.  As part of a plea agreement with the government, Libbert has agreed to serve at least six years in federal prison, and the government has agreed to recommend a sentence of not greater than 20 years. Libbert is scheduled to be sentenced by United States District Judge Cormac J. Carney on March 20, 2017.

“The investigation in this case revealed that this defendant controlled an organization that was one of the largest importers and distributors of dangerous, synthetic drugs in the nation,” said United States Attorney Eileen M. Decker. “Over the course of only 16 months, this organization smuggled well over 600 pounds of chemicals into the U.S., knowing that the drugs would be used to manufacture synthetic marijuana or ‘spice’ that was smoked or taken orally. As the indictment in this case references, these synthetic drugs pose serious health risks to its users.”

The nearly three-year investigation into the analogue drug ring was conducted by the Los Angeles (High-Intensity Drug Trafficking Area) Southern California Drug Task Force, which includes special agents with the Drug Enforcement Administration, U.S. Immigration and Customs Enforcement’s Homeland Security (HSI), and IRS Criminal Investigation.

“Ingesting any synthetic cannabinoid or cathinone is like playing a game of Russian roulette - it can kill you in an instant,” said DEA Special Agent in Charge Steve Comer. “Dismantling the highest level drug manufacturing and distribution organizations in the interest of public health and safety is what DEA is all about, and we’ll continue to target these organizations no matter what facade they operate behind.”

As part of the scheme, Libbert incorporated a series of companies, opened up a series of bank accounts and private mailboxes, and used various websites to sell more than $12 million worth of chemicals and analogue substances to people across the United States, including other distributors and individual users.  Libbert and his co-conspirators also manufactured their own synthetic cannabinoids, which they marketed and sold under the brand “Da Kine Blend.”  When he pleaded guilty, Libbert admitted that over a 7½-month period in 2011 he distributed at least 4 kilograms of synthetic cannabinoids, which he knew would be used to manufacture at least 100 kilograms of synthetic marijuana for human consumption.

“The packaging and names associated with analogue drugs might lead some impressionable users to believe these substances are benign, but the reality is they can cause serious health complications and even death,” said Joseph Macias, Special Agent in Charge for HSI Los Angeles. “Couple that with the fact synthetic drugs are often marketed to young people and you have a prescription for disaster. For that reason, HSI is continuing to work closely with its federal and local law enforcement counterparts to target this emerging side of the illicit drug trade.”
           
In July 2012, HIDTA investigators executed a series of federal search warrants and seized several luxury vehicles, hundreds of pounds of analogues and firearms - including a rifle, a shotgun, two pistols, and approximately 700 rounds of ammunition, all of which Libbert was prohibited from possessing as a result of three prior felony convictions, including a 2002 drug trafficking conviction.

In addition to the drug and firearms charges, Libbert also pleaded guilty to one count of money laundering.  Investigators have seized more than $1.1 million in assets connected to the case, including more than $700,000 in profits from the sale of Libbert’s former San Juan Capistrano home.

“This is an important victory for the American public in federal synthetic drug law enforcement,” stated Acting Special Agent in Charge Anthony J. Orlando of IRS Criminal Investigation. “Not only is Libbert being held accountable for his crime, but he has agreed to the forfeiture of the proceeds associated with his illegal activity through the mechanism of asset forfeiture. IRS Criminal Investigation will continue to financially disrupt and dismantle significant drug trafficking organizations through the seizure and forfeiture of assets associated with the crime."

Previously in this case, two other defendants pleaded guilty, including a Chinese national who sold Libbert and his associates synthetic drugs that were smuggled into the United States. Another three defendants charged in a separate case pleaded guilty to conspiring with Libbert to manufacture and distribute controlled substance analogues. These other five defendants are expected to be sentenced by Judge Carney next year.

Download Press Release
###
US Department of Justice - Drug Enforcement Administration

Drug Enforcement Administration

Matthew W. Allen Special Agent in Charge - Los Angeles
@dealosangeles
  • Facebook
  • X
  • Email

SAMHSA Behavioral Health Treatment Locator

  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Drug Prevention
    • Diversion Control Division
    • News
  • Careers
    • Special Agent
    • Diversion Investigator
    • Forensic Sciences
    • Intelligence Research Specialist
    • How to Apply
  • Resources
    • Drug Information
    • Employee Assistance Program
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
    • Vendor Engagement Request
  • Policies
    • Accessibility & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster

United States Drug Enforcement Administration

Back
  • Who We Are
  • What We Do
  • Careers
  • Resources
Back
  • About
  • Mission
  • History
  • Divisions
  • DEA Museum
  • Wall of Honor
  • Contact Us
Back
  • Domestic Divisions
  • Foreign Divisions
  • Operational Divisions
Back
  • Submit a Tip
  • Extortion Scam
  • Public Affairs
  • Social Media Directory
Back
  • Forensic Sciences
  • Law Enforcement
  • Education and Prevention
  • Drug Information
  • News
  • Campaigns
Back
  • GUARDS
  • Forensic Sciences Policy
  • Forensic Science Organizations
  • Forensic Science Contact
Back
  • DEA Office of Training
  • El Paso Intelligence Center (EPIC)
  • Intelligence
  • Operations
Back
  • Office of Training Programs
Back
  • Administrative Law Judges
  • DEA Asset Forfeiture
  • Domestic Cannabis Suppression / Eradication Program
  • HIDTA
  • OCDETF
Back
  • Family Summit
  • Red Ribbon
  • Kiki and the History of Red Ribbon Week
  • Red Ribbon Toolkit - Resources For Your Community
  • DEA’s Family Summit
  • Operation Engage
  • Community Outreach
  • Just Think Twice
  • Campus Drug Prevention
  • Get Smart About Drugs
  • Operation Prevention
Back
  • Drug Policy
  • Drug Scheduling
  • The Controlled Substances Act
Back
  • Alerts
  • Press Releases
  • Most Wanted Fugitives
  • Stories
  • Events
  • Speeches
  • Testimony
Back
  • All Fugitives
Back
  • One Pill Can Kill
  • DEA National Prescription Drug Take Back Day
Back
  • Senior Citizens
  • Partner Toolbox
  • Social Media Campaign
Back
  • Special Agent
  • Diversion Investigator
  • Intelligence Research Specialist
  • Forensic Sciences Careers
  • Professional & Administrative Careers
  • Student & Entry Level Careers
  • Employment Eligibility
  • How to Apply
Back
  • Special Agent FAQs
Back
  • Diversion Investigator Job Announcement
Back
  • Intelligence Research Specialist Job Announcements
  • Intelligence Research Specialists FAQs
  • Schedule A Hiring Authority: Intelligence Research Specialist
Back
  • How To Claim Veterans' Preference
  • Priority Consideration
  • Benefits
  • Veterans and People With Disabilities
  • Operation Warfighter
Back
  • Illegal Online Pharmacies
  • OD Justice
  • Fentanyl Supply Chain
  • Pill Press Resources
  • Recovery Resources
  • Together for Families
  • Data and Statistics
  • FOIA
  • Publications
  • Media Galleries
  • Victim Witness Assistance Program
Back
  • Domestic Arrests
  • Staffing and Budget
Back
  • About FOIA
  • Contact DEA FOIA
  • Make a Request
  • What Happens After Making a Request
  • Requester Categories
  • Fees Charged
  • Fee Waiver
  • FOIA FAQ
  • FOIA Logs and Reports
  • FOIA Library
  • Additional FOIA Links
  • FOIA Exemptions
  • What Are Exclusions?
  • Privacy Act
  • Privacy Act Exemptions
  • Privacy Impact Assessment and Management Information Systems
Back
  • Victim Witness Assistance Program Resources
  • Human Trafficking Prevention
  • Submit A Tip +
  • Get Updates
  • Scam Alert
    • English
    • Español